SAGE Therapeutics (SAGE) Misses Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
SAGE Therapeutics Announces Second Quarter 2015 Financial Results and Highlights Recent Progress
August 12, 2015 6:30 AM EDTGlobal Phase 3 STATUS Trial to Evaluate SAGE-547 as a Treatment for SRSE Now Open for Enrollment
Novel, Proprietary Second-Generation Product Candidates Poised to Enter Phase 1 in 2015
CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ: SAGE) today reported business highlights and financial results for the second quarter ended June 30, 2015.
"We are pleased to have moved SAGE-547 into Phase 3 development with the initiation of the STATUS Trial, which will be conducted with the U.S. Food and Drug Administration (FDA) agreement under a Special Protocol... More
SAGE Therapeutics Announces Second Quarter 2015 Financial Results and Highlights Recent Progress
August 12, 2015 6:30 AM EDTGlobal Phase 3 STATUS Trial to Evaluate SAGE-547 as a Treatment for SRSE Now Open for Enrollment
Novel, Proprietary Second-Generation Product Candidates Poised to Enter Phase 1 in 2015
CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ: SAGE) today reported business highlights and financial results for the second quarter ended June 30, 2015.
"We are pleased to have moved SAGE-547 into Phase 3 development with the initiation of the STATUS Trial, which will be conducted with the U.S. Food and Drug Administration (FDA) agreement under a Special Protocol... More
